Diagnosis and management of the drug hypersensitivity reactions in Coronavirus disease 19

Creative Commons License

GELİNCİK A., Brockow K., celik G. E., Dona I., Mayorga C., Romano A., ...Daha Fazla

ALLERGY, cilt.75, sa.11, ss.2775-2793, 2020 (SCI-Expanded) identifier identifier identifier

  • Yayın Türü: Makale / Derleme
  • Cilt numarası: 75 Sayı: 11
  • Basım Tarihi: 2020
  • Doi Numarası: 10.1111/all.14439
  • Dergi Adı: ALLERGY
  • Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, Agricultural & Environmental Science Database, BIOSIS, CAB Abstracts, EMBASE, Food Science & Technology Abstracts, MEDLINE, Veterinary Science Database
  • Sayfa Sayıları: ss.2775-2793
  • Anahtar Kelimeler: COVID-19, desensitization, drug hypersensitivity reactions, SARS-CoV-2, CHRONIC HEPATITIS-C, GENERALIZED EXANTHEMATOUS PUSTULOSIS, TOXIC EPIDERMAL NECROLYSIS, IGE-MEDIATED HYPERSENSITIVITY, ALLERGIC CONTACT-DERMATITIS, SKIN-TEST CONCENTRATIONS, IMMEDIATE HYPERSENSITIVITY, SUCCESSFUL DESENSITIZATION, RAPID DESENSITIZATION, INTERFERON-BETA
  • Hacettepe Üniversitesi Adresli: Evet

Özet

Coronavirus disease 2019 (COVID-19), a respiratory tract infection caused by a novel human coronavirus, the severe acute respiratory syndrome coronavirus 2, leads to a wide spectrum of clinical manifestations ranging from asymptomatic cases to patients with mild and severe symptoms, with or without pneumonia. Given the huge influence caused by the overwhelming COVID-19 pandemic affecting over three million people worldwide, a wide spectrum of drugs is considered for the treatment in the concept of repurposing and off-label use. There is no knowledge about the diagnosis and clinical management of the drug hypersensitivity reactions that can potentially occur during the disease. This review brings together all the published information about the diagnosis and management of drug hypersensitivity reactions due to current and candidate off-label drugs and highlights relevant recommendations. Furthermore, it gathers all the dermatologic manifestations reported during the disease for guiding the clinicians to establish a better differential diagnosis of drug hypersensitivity reactions in the course of the disease.